Clinigen is a global pharmaceutical services and products company focused on providing ethical access to medicines with a mission to deliver the right medicine to the right patient at the right time. The business operates from sites in North America, Europe, Africa and Asia Pacific.
Numis is proud of our long-standing relationship with Clinigen. It is a business we first IPO’d in 2012 and have supported the company on its organic and inorganic growth strategy in the years since.
The offer price of 925p per share, which was the seventh of seven unsolicited proposals from Triton, represented a 48% premium to the (ex-div) closing price and a 50% premium to the six-month volume weighted average (ex-div) price at close of business on 1 December 2021, the last business day before the start of the offer period.
The Numis team provided key input on value and tactics, as well as process management and shareholder insight.